Treace Medical Concepts, Inc. (TMCI)
NASDAQ: TMCI · Real-Time Price · USD
4.440
+0.020 (0.45%)
At close: Nov 17, 2026, 4:00 PM EST
4.430
-0.010 (-0.23%)
After-hours: Nov 17, 2026, 7:30 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

New products expanded access across bunion, midfoot and hindfoot procedures, supporting double-digit Q3 case volume growth. Management expects revenue growth in Q4 2026 and adjusted EBITDA profitability in 2027, with further product launches planned.

Rick Wise
Analyst, Stifel

And even make it on time. I do not know what that says, but it is a tough start. It is downhill from here, John.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

I hope so.

Rick Wise
Analyst, Stifel

But no, thank you so much for being here. We have Mark Hair, apparently number one Manager, CFO at the top there. Oh, and there is John Treace, Founder, Chairman, and CEO also. Thank you both for being here. We really appreciate it.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

Thanks for having us, Rick.

Rick Wise
Analyst, Stifel

As those in the audience and listening know, I'm very excited about the Treace story. We upgraded this stock just a couple days ago, and it really feels like after, John, just to start at a high level, after several years of intense work on the innovation front, the commercial front, I'm calling it a reboot. It's like this is Treace, I'll call it 2.0. Maybe it's 3.0. What's your big picture perspective on where you've been and where you are now?

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

No, great. Thanks for having us again. Six year here. It's a pleasure and honor. As I look through the progression of Treace Medical, it started with a real innovation in the bunion space. How do you fix this problem that's very prevalent, affects 65 million Americans, and recurrence rates are anywhere between 20% and up to 80% in the clinical literature? We developed Lapiplasty to be a comprehensive solution, fix all three planes of the bunion correction. We drove that into the marketplace successfully, IPO in mid-2021, got access to more funds, and started to look at where do we go next with our product development. We were beginning to see this trend of minimally invasive osteotomies becoming more popular in the marketplace for treating bunions. We were also seeing more need for MTP fusion.

As the baby boomer population was aging, those bunion patients had more arthritic toe joints.

More surgeons were starting to shift these procedure preferences around a bit. With the funds from the IPO, we were able to invest in an innovation pipeline, and that spit out the three new bunion solutions we brought into the market in Q3 of 2025. What we've been doing up until now is driving those deep into our base of 3,300+ surgeon customers. If you look at from a broader perspective, with Lapiplasty, as successful as it was and as user-friendly as it was and as great as the outcomes were, we were only getting about 25% of our overall surgeons' bunion business. Those three bunion solutions were made to go after the other 75% and address those preference shifts. Q4 of last year, after launching them in Q3, they were in the hands of about 25% of our overall surgeon customer base.

As we sat in Q3, we announced we had them in 45%. 45% of our customer base had used one or more of those three new bunion systems in their practice, and that is up from, we have been sequentially increasing about 5% over the last few quarters. We are making really good progress there. That was wave two, I would say. Lapiplasty, wave one, the three new bunion systems, wave two. How do we go after the big volume? 70% of the bunion volume were in the space that those three new bunion systems served. Now we recently announced the launch of several new technologies targeting the midfoot and the hindfoot, and more broadly allowing us to access procedures throughout the foot and ankle, that TAM expansion of $700 million that we talked about. All of that is building our case volumes.

We announced a double-digit case volume growth in the third quarter. We were more like single digits in the low single digits in the first quarter, second quarter, high single digits. Now we are double digits, and we are translating that to positive top-line growth as we enter Q4. Maybe a little longer answer than you wanted, but wanted to give you the whole rundown. It is a great position to be in. We are really excited. We are also excited about the enhancements in our profitability. adjusted EBITDA positive for the first time ever in a Q3.

We are typically in Q4. 50% reduction in our cash, broadened portfolio, and our salespeople are more productive. They are in more cases. We are doing more procedures than ever, and we are excited to return to top-line growth in Q4.

Rick Wise
Analyst, Stifel

I am excited for you. That is a great summary and a great way to start. How do we think about this cadence of technology that basically is in hand and visible to us? I know some of the products are in full market release, some are in limited market release, but you have been very clear about the cadence and what is ahead in 2027. How confident are you that you can introduce all these products coherently, consistently, optimally, and manage this whole next evolution?

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

We feel great about it, actually. The products we've introduced at the 2026 launches, we announced on that third quarter call, we're tapping into the same customer base, and typically they're going to be the same procedures that occur the same day as the bunion surgeries our sales reps are already in.

Rick Wise
Analyst, Stifel

I see.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

They occur within the same week. So they all have, we believe, best-in-class features and bring real benefits, whether it's time savings to the case, saving steps, or making the outcomes more predictable. So they all have those nuances that Treace Medical's been known for. Whenever we launch something, surgeons know it's going to be worth looking at.

Rick Wise
Analyst, Stifel

Right.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

The stick rate is pretty high. We talked about the 45% that had used one of the three new bunion systems. The majority of those are repeat customers. We know that the majority of them are using it multiple times, and a lot of those customers are pretty new, so there's still more opportunity to do more with them.

Rick Wise
Analyst, Stifel

A couple things I'm not as clear on as I would like to be. Do the new products, and I put a chart in my upgrade note that sort of lists them all, do those products address completely the other 75% of bunion procedures, if you see what I'm asking? Or do you need are there other products you haven't yet spoken about in the pipeline, and there's even more to come?

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

I would say between Lapiplasty, Adductoplasty, so Lapiplasty is the comprehensive fix at the point of the deformity apex. Adductoplasty, where you have the midfoot deformity, and we have two minimally invasive osteotomy options and the MTP option. We believe we've got basically 100% of the bunion preferences encircled—

Rick Wise
Analyst, Stifel

Okay.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

—for our surgeons with that platform. The midfoot platform, our SuperBite screw line, SuperBite screws, compression screws are used throughout the foot. It's the most prevalently used form of fixation. We just launched that in Q3. That's had the highest uptake, the fastest into our customer base of any product we've launched.

And what that's allowed to happen is our salespeople to get invited into a lot of midfoot and hindfoot surgeries. Some of these have pretty high price points per case, and that helps balance out a little bit of the lower ASP new bunion products too.

Rick Wise
Analyst, Stifel

Interesting.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

Between those technologies, we can access about 80%. Some surgeons are telling us we can access about 90% of their reconstructive foot and ankle surgeries. You go from a company that just over a year ago only treated a third of their bunions to a year ago now treating all of their bunions, and now we are at a point where we are treating the majority of the foot. And we are just starting this third wave of innovation, this third wave of advancing our sales force's position to take market share throughout the foot and in parts of the ankle.

Rick Wise
Analyst, Stifel

What is your big picture perspective on this market? Is it growing? And I feel like you are uniquely positioned to grow even if the consumer slightly falters and the economy slows, given all these new markets you are entering. But should we be concerned about that factor as we think about the year ahead? Are you concerned about it?

Mark Hair
CFO, Treace Medical Concepts

Maybe I will jump in there, Rick.

Rick Wise
Analyst, Stifel

Okay. Please.

Mark Hair
CFO, Treace Medical Concepts

If it's okay. We talked a little bit last year that we saw some softness in what we were kind of consider our normal trends, which are mid-single digits in the foot and ankle market as far as annual growth rates, and that slowed down last year. Some of our data sources suggest that it was maybe flat and maybe even possibly down last year.

Rick Wise
Analyst, Stifel

Market as a whole.

Mark Hair
CFO, Treace Medical Concepts

The market as a whole.

Rick Wise
Analyst, Stifel

Right.

Mark Hair
CFO, Treace Medical Concepts

At least the elective procedures where we were participating. Last year was a little tougher. We don't have absolute visibility into this year, but it seems like it's improving a little bit versus last year. As we thought about this year, we didn't anticipate or include any improvements from what had kind of happened last year. I think one of the real takeaways is, if in fact the spaces, these market, foot and ankle market segments are growing very low single digits, I think that really even puts a finer point on the fact that we just reported double-digit case volume in Q3. Meaning, even with the market maybe being off from historical trends, I think we're doing really important things. It's a validation that the strategy is working.

We are getting the cases that we did not get before, and our sales reps now have the opportunity to be a more trusted partner with their surgeon customers, be in the OR more often, and introduce these new products. We feel it is validation, and by comparison to what the market we believe is doing, I think right now, from a case volume perspective, we are definitely outpacing the market.

Rick Wise
Analyst, Stifel

Yeah. Makes sense. John, what kind of competitive response do you envision, do you fear, should we fear? How easily can your large or small competitors imitate your excellent innovation and get after you?

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

Well, we have a hearty respect for all competitors. What we are really good at doing is innovating instrumentation and advancing it quickly, iterating it quickly.

When surgeons get our generation one of a Percuplasty jig or a Nanoplasty jig or Lapiplasty, they know that within six months and maybe a year, it will be advanced and tweaked and adjusted to make it better and better and better. That is what we are great at, and that is what helps us be sticky. Number two, we got a direct sales channel that makes up 80% of our revenue that only sell our products, and they know these procedures really, really well. That is a big help in the OR with surgeons that are learning and trying to lock in the way of doing a new procedure.

Our training, our Bunion Masters events, these are surgeon training events where we have a simulated live surgical environment. If you want to become excellent at bunion surgery, I think we've got a very strong reputation in the industry of Bunion Masters is the place to go if you want to really, really do great at that type of surgery. Bunion surgery is such a high volume, it's such an MTP fusion, it's such a large part of what the surgeons do in their practice, it creates a lot of referrals. Being the best you can be as a surgeon in those procedures creates a lot of, I would say, side benefits for those surgeons too.

Rick Wise
Analyst, Stifel

Let's dig a little bit into revenue per procedure. You mentioned it, Mark, as well, and John, both of you. Case volume is growing nicely, as you said, John. Revenue per procedure has been declining because of this mix shift offset by the midfoot screws, et cetera. I think this is a question that I've gotten most. People are confused about it. People don't Is this negative? Do we ever lap this kind of process and can grow at the rate that cases are growing? How should we what are people not understanding that you understand that we should understand about this dynamic?

Mark Hair
CFO, Treace Medical Concepts

Rick, maybe I'll jump in on that, and John can add some additional color as well, I'm sure. As we think about what we just went through in Q3, I think it's helpful to understand some of the dynamics that occurred in the quarter. One thing we had talked about last year and then again on our most recent call last week is that there was a little bit of a headwind that we had.

Rick Wise
Analyst, Stifel

Right.

Mark Hair
CFO, Treace Medical Concepts

This headwind, we knew it was there, and it related to the way we were going to market with some of these new product offerings last year. We had some distributors of ours that were stocking some of these new products and in anticipation of these product launches. Q3 of last year, to facilitate that commercialization of these products, we had about $6 million that was purchased by these distributors. When you compare it to this year, it was less than $1 million. That created about a $5 million differential year-over-year. If you exclude just the way we were going to market and exclude that channel, that stocking distributor channel, although we reported Q3 revenue declining 4%, if you exclude that channel, we actually grew mid-single digits.

Again, I think it's validation that the top line is or that the case volume growth is growing, and the differential still exists because our revenue didn't equal the case volume growth, but it's getting there, and it's getting closer. Over time, that mix shift won't be as dramatic because these new products will be out there, and as we anniversary their launches, it will be closer that the revenue top line growth will be closer to the case volume growth.

Rick Wise
Analyst, Stifel

To matching the case volume.

Mark Hair
CFO, Treace Medical Concepts

To match it.

Rick Wise
Analyst, Stifel

Right. In 2027, that seems to be the setup.

Mark Hair
CFO, Treace Medical Concepts

It seems to be, and it will be. Now, with that said, we continue. John has already talked about some of the new products that we are launching just this year, and we have an anniversary of the new product launches that are coming this year and those products that are coming early next year. And there is more to come, frankly.

Rick Wise
Analyst, Stifel

Yeah.

Mark Hair
CFO, Treace Medical Concepts

We are not done yet.

Rick Wise
Analyst, Stifel

Are you stocking now the same way as you launch each one?

Mark Hair
CFO, Treace Medical Concepts

I think the dynamic that existed was when they took their initial position, they needed to have higher volumes to have in their warehouse, have in the trunk stock, and just to run their businesses—

Rick Wise
Analyst, Stifel

I see.

Mark Hair
CFO, Treace Medical Concepts

—as stocking distributors. But on a recurring basis, those levels have dropped. This year, it has been closer to around $1 million a quarter.

Rick Wise
Analyst, Stifel

I see.

Mark Hair
CFO, Treace Medical Concepts

As that just becomes a normal run rate, we just do not have the same headwinds.

Rick Wise
Analyst, Stifel

Anything, I didn't want to cut you off, John, if you had something else to say.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

No.

Rick Wise
Analyst, Stifel

Hate to talk about guidance. Actually, I don't at all. Third quarter, you beat by a 500,000 , and as I said in my note, 12th quarter in a row where you've exceeded consensus numbers. It's impressive. I can think of a lot of other larger companies that I wish would emulate your guidance thoughtfulness. But you kept the guide for the year. Is that just thoughtful prudence, anxiety about the fourth quarter? What's behind that?

Mark Hair
CFO, Treace Medical Concepts

Yeah, I think we It's a great question, and as we thought about the quarter, we had a modest beat in Q3. It wasn't very substantial, and really nothing changed with our outlook on Q4, so we just felt like let's just keep it right where it is. Q4 for us, again, it's a seasonally high elective procedure volumes, and there was nothing that really caused us to make any dramatic changes. Again, it's validating that we have these high case volumes, we've got these new products, and for this year, we just felt like it's the right thing to do is just to maintain that outlook for the fourth quarter and for the rest of the year.

Rick Wise
Analyst, Stifel

And this is the moment where, my favorite moment, where every CFO turns ashen. Let's talk about 2027. The Street and I also am at 5% growth for next year. It just feels like everything I'm hearing and seeing and the new product launches and this, you're going to penetrate more doctors who are going to try for the first time. You're going to see more re-order rates. The mix is going to keep improving. Why shouldn't I be at a higher number for next year, Mark?

Mark Hair
CFO, Treace Medical Concepts

First of all, I actually love talking about next year. This year has been a little bit of a challenge to explain the excitement, to explain the case volume growth, but not show it on the top line. What we know is we are going to exit this year with top line revenue growth. It is going to be great to return to that growth. We know that we will have top line growth next year. We are very excited. We think the setup is great as we come into next year. A couple things that we just want to have is Q4 is actually a very important quarter for us. Our volumes, we have had quarters and years where Q3 to Q4 can increase 30%, 40%, 50% on volume. It becomes a very important quarter for us to understand what are the current trends in the marketplace?

What are we seeing? What is the market growth for the year? We also have introduced some new products as well. We think it is important to see how are these new products, what is the uptake like, how are surgeons using these new products? I think we learn a lot from the fourth quarter. This year will be no different from any other year. I think this is, John mentioned six years at the Stifel conference and six years of the same question. We will give our annual guidance on our Q4 call, which will be early next year. Then we will have the fourth quarter behind us, and we will have a better insight and understanding about the uptake of our new products, as well as what we are seeing in the marketplace. We are looking forward to 2027.

I mean, there is a lot of reason to be excited with this new product line. We have a lot of internal excitement, and we look forward to when we are going to translate some of this volume increases into top-line revenue. This has been a hard year for us to not have that, and based on what we have seen so far, we are pleased that we are going to exit this year with that momentum.

Rick Wise
Analyst, Stifel

Thank you for that. Profitability, I thought that the fact that you reported on the plus side of positive in the third quarter for your adjusted EBITDA was a milestone, and you have guided to now a $1 million-$3 million adjusted EBITDA loss for the year. How do you want us to think about the direction of this line going forward? Is John pressuring you to allow him to spend more or to launch all these great new products, or how are you balancing the desire for growth and—

Mark Hair
CFO, Treace Medical Concepts

Yeah.

Rick Wise
Analyst, Stifel

—profitability there?

Mark Hair
CFO, Treace Medical Concepts

Another great topic. We are very pleased, and I appreciate that you are calling it a milestone. We are pleased with the progress that we have made. We reported positive adjusted EBITDA in the third quarter, the first time that we have done that outside of our seasonally high fourth quarter.

We are pleased with that. I do not think we are satisfied with it. There is more to come. A lot of the changes we made when we were talking last year, we made some changes to our cost structure last year that we knew would annualize, we would benefit this year. A lot of the decisions have already been made. We took some changes to the organization last year. We have cut out and reduced some costs. It has allowed us still to innovate, to continue to bring new products, to have the necessary capital for our capitalized surgical instrumentation.

We are able to do everything that we need to do. We are committed to the top line, but we are committed to also making sure that we are doing it prudently and to have some improvement on the bottom line as well. Fourth quarter, we fully anticipate to have positive adjusted EBITDA. We do every fourth quarter, and we look forward to it this year. We think we can improve upon our guide. Our guide for adjusted EBITDA was actually a loss of $1 million-$2 million.

Rick Wise
Analyst, Stifel

I wrote it wrong, sorry.

Mark Hair
CFO, Treace Medical Concepts

No, that's okay. It's actually a little bit better than—

Rick Wise
Analyst, Stifel

Yes.

Mark Hair
CFO, Treace Medical Concepts

—what you stated in the question. We think we should be able to do that, and we look forward to hitting that and perhaps doing even better. Then as we think about next year, being fully positive for the full year next year is really what we anticipate.

Rick Wise
Analyst, Stifel

John, stepping back and looking at the big picture of the next few years, I mean, it's clear that 2027, the setup is positive, as Mark has said as well. But how do we think about the next two, three, four years at Treace? Is this a product cycle that once it's done and you've gotten the adoption you're going to get, what comes after that? How are you thinking about what's your longer-term vision for the company, and where can you go with technology or products or markets?

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

Yeah, great question. I think it's important for this company, we're only about 8% penetrated into the bunion opportunity, right? We've got best-in-class solutions now around a lot of that. Keeping that anchor point and keeping best-in-class technology leader experts in that part of the foot and ankle market is critical to us. But developing a broader foot and ankle business off of that anchor position is becoming equally as important to us. The 2026 launch is a TAM-expanding group of products, five products that we talked about. That's just the beginning. We've got a rich pipeline of new launches targeting new solutions in 2027 and 2028, and we'll have one beyond that. But every time we get into a new area of anatomy and surgical procedure, we see ways that our engineers and our great thoughtful surgeons can work together to make them better.

I think we're touching the tip of the iceberg in the new areas, the midfoot and the back of the foot and maybe the ankle, bringing more technologies to be more comprehensively serving the surgeon's needs, but then also developing some real procedure-enhancing, changing that surgeon experience for the better in a lot of these cases. We're known for great instrumentation, we're known for great implants, and I think you're going to continue to see a great proliferation of those as we go forward for the next several years. The other area that we didn't talk about as much today is how we're going to advance Lapiplasty. We're looking forward to our first commercial wave launch in Q1 of our Lightning instrumentation. Makes it faster, lets the surgeon dial in the three-plane correction that we're known for, even with more precision.

Our IntelliGuide PSI, very exciting technology. Take a CT scan, software engineers do the whole correction in software, send the surgeon a personalized 3D cutting guide to fix the whole deformity, once it's put in the surgeon's hands and put on the patient. This is saving time, it's letting surgeons do procedures that they maybe before thought weren't possible in their hands.

You know, severe deformities. We're looking at ways that we can more fully automate that and scale that as we go forward, because we think that's a strong part of the future.

Rick Wise
Analyst, Stifel

I'm so glad you brought this up because I had an earlier question and I skipped over it. Are these products on the Lapiplasty side with higher ASPs and better margins, or does that change some of the growth and reporting dynamics of that part of the business?

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

Yeah. Currently, I would say the Lapiplasty Lightning and those constructs are going to be a similar price point. Where we're seeing higher price points, beyond Lapiplasty, is in the IntelliGuide PSI. That is a higher price point. We sell the cutting guides that we've developed with the software with the surgeon, and then you have the implant. So those end up being a higher ASP price point. Those are some of the things that can offset the lower ASP of some of the newer bunion products over time. So we're not just accepting that we're going to have a drag on our price per case.

Rick Wise
Analyst, Stifel

Right.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

We're actively working on counter strategies with the product line and how we evolve the product line to balance that out over time too.

Rick Wise
Analyst, Stifel

One last question I wanted to come back to, Mark, maybe as we wrap up. You have done an excellent job, and John as well, this year of cutting costs. I mean, operating expense numbers, dollars are down, I think in each quarter this year-over-year. How much more opportunity is there? Is there, pay the CFO less or, I mean, what's next?

Mark Hair
CFO, Treace Medical Concepts

That is always on the table.

Rick Wise
Analyst, Stifel

John made me say that.

Mark Hair
CFO, Treace Medical Concepts

That is always on the table. Well, like I said, a lot of the changes that we made last year we are benefiting from this year. I think we are just committed as a company to ensure that we are investing in the right places. I do not think there is a dramatic focus to change or restructure the organization. I do not think that is necessary. I just think it is going to be prudent decisions along the way to prioritize top line growth and to do that efficiently and effectively throughout the P&L. I do believe that we can be, from an adjusted EBITDA perspective, positive next year. We are going to be nipping at it this year, and that is a nice improvement year-over-year, and we have made steady improvements the last several years.

We fully anticipate to have additional improvements into next year, and we can do that in a way that is not going to limit our ability to grow the top line.

Rick Wise
Analyst, Stifel

Really the positive drop-through operating leverage part of the story maybe is an underappreciated aspect of Treace today.

Mark Hair
CFO, Treace Medical Concepts

Well, yeah. I think there was a huge change year-over-year when you look at Q3, and even from what the expectations were. I mean, that was actually something we were very proud of, and we will continue to focus in that area.

Rick Wise
Analyst, Stifel

That is great. On that note, I thank you both for being here and putting up with me, but exciting to see all the positive change. Congratulations.

Mark Hair
CFO, Treace Medical Concepts

Thanks, Rick.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

Thank you, Rick. Appreciate it.

Rick Wise
Analyst, Stifel

Look forward to this time next year. Let's see.

John Treace
Founder, Chairman, and CEO, Treace Medical Concepts

All right, number seven.

Mark Hair
CFO, Treace Medical Concepts

Thanks, Rick.